

PTO/SB/08A (08-03)

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

810

Complete if Known

Application Number	09/724,288
Filing Date	November 28, 2000
First Named Inventor	Schenk, Dale B.
Art Unit	1649
Examiner Name	Sharon L. Turner K. Ballard
Attorney Docket Number	15270J-004765US

U.S. PATENT DOCUMENTS+

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code ² (if known)			
KAB	686	6,972,127	12-06-2005	Schenk	
	679	2005/0255122 A1	11-17-2005	Schenk	
	680	2005/0249727 A1	11-10-2005	Schenk	
	674	6,962,707	11-08-2005	Schenk	
	656	6,946,135	09-20-2005	Schenk	
	693	2005/0191314 A1	09-01-2005	Schenk	
	713	6,936,698	08-30-2005	Taylor	
	716	6,933,368	08-23-2005	Co et al.	
	685	2005/0163788 A1	07-28-2005	Schenk	
	657	6,913,745	07-05-2005	Schenk	
	715	2005/0136054 A1	06-23-2005	Adair et al.	
	658	6,905,686	06-14-2005	Schenk	
	714	2005/0123534 A1	06-09-2005	Adair et al.	
	659	6,890,535	05-10-2005	Schenk	
	683	2005/0059802 A1	03-17-2005	Schenk et al.	
	684	2005/0059591 A1	03-17-2005	Schenk et al.	
	661	2005/0009150 A1	01-13-2005	Basi et al.	
	583	2004/0265919 A1	12-30-2004	Vanderstichlele et al.	
	581	2004/0247612 A1	12-09-2004	Wang	
	582	2004/0241164 A1	12-02-2004	Bales et al.	
	673	6,808,712	10-26-2004	Schenk	
	667	6,787,523	09-07-2004	Schenk	
	670	6,787,144	09-07-2004	Schenk	
	668	6,787,143	09-07-2004	Schenk	
	672	6,787,140	09-07-2004	Schenk	
	669	6,787,138	09-07-2004	Schenk	
	671	6,787,129	09-07-2004	Schenk	
	660	2004/0171815 A1	09-02-2004	Schenk et al.	
	708	2003/0039645 A1	10-14-2003	Adair et al.	
	675	6,710,226	02-23-2004	Schenk	
	712	6,639,055	10-28-2003	Carter et al.	
	709	6,632,927	10-14-2003	Adair et al.	
	730	2003/0166557 A1	09-04-2003	Minna et al.	
	702	6,548,640	04-15-2003	Winter	
KAB	725	6,538,124	03-25-2003	Idusogie et al.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

37305_1




PTO/SB/08A (08-03)

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known	
Application Number			09/724,288	
Filing Date			November 28, 2000	
First Named Inventor			Schenk, Dale B.	
Art Unit			1649	
Examiner Name			Sharon L. Turner K. Ballard	
Attorney Docket Number			15270J-004765US	
Sheet	2	of	810	

U.S. PATENT DOCUMENTS+						
Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
KAB	726	6,528,624		03-04-2003	Idusogie et al.	
↓	710	6,407,213		06-18-2002	Carter et al.	
	720	6,277,375		08-21-2001	Ward	
	724	6,194,551		02-27-2001	Idusogie et al.	
	704	6,180,370		01-30-2001	Queen et al.	
	719	6,165,745		12-26-2000	Ward et al.	
	723	6,121,022		09-19-2000	Presta et al.	
	711	6,054,297		04-25-2000	Carter et al.	
	722	5,869,046		02-09-1999	Presta et al.	
	707	5,859,205		01-12-1999	Adair et al.	
	642	5,702,906		12-30-1997	Rosenthal	
	643	5,693,762		12-02-1997	Queen et al.	
	705	5,693,761		12-02-1997	Queen et al.	
	721	5,677,425		10-14-1997	Bodmer et al.	
	717	5,648,260		07-15-1997	Winter et al.	
	718	5,624,821		04-29-1997	Winter et al.	
	644	5,618,920		04-08-1997	Robinson et al.	
	584	5,589,154		12-31-1996	Anderson	
	706	5,585,089		12-17-1996	Queen et al.	
	619	5,530,101		06-25-1996	Queen et al.	
	645	5,258,498		11-02-1993	Huston et al.	
703	5,225,539		07-06-1993	Winter		
646	4,816,567		03-28-1989	Cabilly et al.		
647	4,816,397		03-28-1989	Boss et al.		
↓	691	11/245,524		filed 10-07-2005	Schenk	
KAB	692	11/245,916		filed 10-07-2005	Schenk	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



PTO/SB/08A (08-03)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete If Known		
			Application Number	09/724,288	
			Filing Date	November 28, 2000	
			First Named Inventor	Schenk, Dale B.	
			Art Unit	1649	
			Examiner Name	Cheron L. Turner K. Ballard	
Sheet	3	of	810	Attorney Docket Number	15270J-004765US

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cita No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
KAB	633	WO	96/08665	A2	03-21-1996			
	630	WO	95/17085	A1	06-29-1995			
	696	WO	95/06407	A1	03-09-1995			
	736	WO	94/10569	A1	05-11-1994			
	648	WO	91/09967	A1	07-11-1991			
	738	EP	626 390	A1	11-30-1994			
	737	EP	620 276	A1	10-19-1994			
	632	JP	07-132033	A	05-23-1995			abs t. onl y
	631	JP	62-267297	A	11-19-1987			abs t. onl y
	701	WO	05/014041	A2	02-17-2005			
	585	WO	04/080419	A2	09-23-2004			
KAB	586	WO	03/077858	A2, A3	09-25-2003			

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

37305_1




Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known	
			Application Number	09/724,288
			Filing Date	November 28, 2000
			First Named Inventor	Schenk, Dale B.
			Art Unit	1649
			Examiner Name	Sharon L. Turner K. Ballard
			Attorney Docket Number	15270J-004765US
Sheet	4	of	810	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
KAB	663	ALBERTS et al., eds. <i>Molecular Biology of The Cell, Third Edition</i> , chapter 23, pages 1208-1209 (1994).	
	649	AMIT et al., "Three-Dimensional Structure of an Antigen-Antibody Complex at 2.8 Å Resolution," <i>Science</i> , 233:747-753 (1986).	
	588	ANDERSON, J. P., "Exact cleavage site of Alzheimer amyloid precursor in neuronal PC-12 cells," <i>Neuroscience Letters</i> , 128(1):126-128 (1991).	
	589	ANDERSON, M. W., "Amending the amyloid hypothesis," <i>The Scientist</i> , 18(20):28-29 (2004).	
	677	ANKARCRONA et al., "Biomarkers for apoptosis in Alzheimer's disease," <i>Int. J. Geriatric Psychiatry</i> , 20:101-105 (2005).	
	681	AULD et al., "Alzheimer's disease and the basal forebrain cholinergic system: relations to β-amyloid peptides, cognition, and treatment strategies," <i>Progress in Neurobiol.</i> , 68:209-245 (2002).	
	590	BACSKAI et al., "Non-Fc-mediated mechanisms are involved in clearance of amyloid-β in vivo by immunotherapy," <i>J. Neurosci.</i> , 22(18):7873-7878 (2002).	
	639	Chimicon International, "Mouse Anti Amyloid Beta Protein Monoclonal Antibody," Catalog # MAB1561 No Date. Do not print.	
	591	CHROMY et al., "Self-assembly of Aβ(1-42) into globular neurotoxins," <i>Biochemistry</i> , 42(44):12749-12760 (2003).	
	592	CITRON et al., "Evidence that the 42- and 40- amino acid forms of amyloid-β protein are generated from the β-amyloid precursor protein by different protease activities," <i>PNAS</i> , 93(23):13170-13175 (1996).	
	593	CITRON, M., "Alzheimer's disease: treatments in discovery and development," <i>Nat. Neurosci.</i> , 5:1055-1057 (2002).	
	699	CLAYTON et al., "Synucleins in Synaptic Plasticity and Neurodegenerative Disorders," <i>J. Neurosci. Res.</i> , 58:120-129 (1999).	
↓	687	COX et al., "Adjuvants---a classification and review of their modes of action," <i>Vaccine</i> , 15(3):248-256 (1997).	
KAB	689	DE LUSTIG et al., "Peripheral Markers and Diagnostic Criteria in Alzheimer's Disease: Critical Evaluations," <i>Rev. In Neurosciences</i> , 5:213-225 (1994).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.




Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known	
			Application Number	09/724,288
			Filing Date	November 28, 2000
			First Named Inventor	Schenk, Dale B.
			Art Unit	1649
			Examiner Name	Sharon L. Turner K. Ballard
			Attorney Docket Number	15270J-004765US
Sheet	5	of	910	

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
KAB	594	DEMATTO et al., "Brain to plasma amyloid- β efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease," <u>Science</u> , 295(5563):2264-2267 (2002).		
	698	Dictionary.com definition of "prophylactic", pages 1-3 downloaded from internet 10/12/05.		
	735	DI MARTINO et al., "Production and Characterization of Antibodies to Mouse Scrapie-Amyloid Protein Elicited by Non-carrier Linked Synthetic Peptide Immunogens," <u>J. Molecular Recognition</u> , 4(2-3):85-91 (1991).		
	595	DODART et al., "Immunization reverses memory deficits without reducing brain A β burden in Alzheimer's disease model," <u>Nat. Neurosci.</u> , 5(5):452-457 (2002).		
	596	DODEL et al., "Immunotherapy for Alzheimer's disease," <u>Lancet Neurol.</u> , 2(4):215-220 (2003).		
	597	DOVEY et al., "Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain," <u>J. Neurochem.</u> , 76(1):173-181 (2001).		
	598	DUFF et al., "Increased amyloid- β 42(43) in brains of mice expressing mutant presenilin 1," <u>Nature</u> , 383(6602):710-713 (1996).		
	599	ERIKSEN et al., "NSAIDs and enantiomers of flurbiprofen target γ -secretase and lower A β 42 in vivo," <u>J. Clin. Invest.</u> , 112(3):440-449 (2003).		
	600	FINDEIS, M. A., "Approaches to discovery and characterization of inhibitors of amyloid β -peptide polymerization," <u>Biochem. Biophys. Acta</u> , 1502(1):76-84 (2000).		
	650	FOOTE et al., "Antibody Framework Residues Affecting the Conformation of the Hypervariable Loops," <u>J. Mol. Biol.</u> , 224:487-499 (1992).		
	601	FRENKEL et al., "Reduction of β -amyloid plaques in brain of transgenic mouse model of Alzheimer's disease by EFRH-phage immunization," <u>Vaccine</u> , 21(11-12):1060-1065 (2003).		
	602	FRENKEL et al., "Towards Alzheimer's β -amyloid vaccination," <u>Biologicals</u> , 29(3-4):243-247 (2001).		
KAB	603	GELINAS et al., "Immunotherapy for Alzheimer's disease," <u>PNAS</u> , 101(suppl. 2):14657-14662 (2004).		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.



PTO/SB/08B (08-03)

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete If Known		
			Application Number	09/724,288	
			Filing Date	November 28, 2000	
			First Named Inventor	Schenk, Dale B.	
			Art Unit	1649	
			Examiner Name	Sharon L. Turner K. Ballard	
			Attorney Docket Number	15270J-004765US	
Sheet	6	of	10		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
KAB	634	Genbank Accession number AAB48800, "Anti-DNA immunoglobulin light chain IgG [Mus musculus]," 09/14/01.		
	635	Genbank Accession number CAA46659, "IgE antibody light chain(VJ)," 06/15/93.		
	636	Genbank Accession number X65775.1, "M.musculus DNA for IgE antibody light chain (VJ)," 06/15/93.		
	637	Genbank Accession number AAD26773, "Immunoglobulin heavy chain VH3609-JH3 region [Mus musculus]," 04/22/99.		
	604	GONG et al., "Alzheimer's disease-affected brain: presence of oligomeric A β ligands (ADDLs) suggests a molecular basis for reversible memory loss," <u>PNAS</u> , 100(18):10417-10422 (2003).		
	605	GREENBERG et al., "Alzheimer disease's double-edged vaccine," <u>Nat. Med.</u> , 9(4):389-390 (2003).		
	694	GUPTA et al., "Adjuvants for human vaccines---current status, problems, and future prospects," <u>Vaccine</u> , 13(14):1263-1275 (1995).		
	606	HAASS, C., "New hope for Alzheimer disease vaccine," <u>Nat Med.</u> , 8(11):1195-1196 (2002).		
	664	HARLOW et al., eds., <i>Antibodies: A Laboratory Manual</i> , pages 71-82 (1998).		
	607	HOCK et al., "Generation of antibodies specific for β -amyloid by vaccination of patients with Alzheimer disease," <u>Nat. Med.</u> , 8(11):1270-1275 (2002).		
	662	IDA et al., "Analysis of Heterogeneous β A4 Peptides in Human Cerebrospinal Fluid and Blood by a Newly Developed Sensitive Western Blot Assay," <u>J. Biol. Chem.</u> , 271(37):22908-22914 (1996).		
	608	IRIZARRY et al., "Alzheimer disease therapeutics," <u>J. Neuropathol. Exp. Neurol.</u> , 60(10):923-928 (2001).		
KAB	609	JANUS et al., "Transgenic mouse models of Alzheimer's Disease," <u>Physiol. Behav.</u> , 73(5):873-886 (2001).		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.



PTO/SB/08B (08-03)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	09/724,288	
			Filing Date	November 28, 2000	
			First Named Inventor	Schenk, Dale B.	
			Art Unit	1649	
			Examiner Name	Sharon L. Turner K. Ballard	
Sheet	7	of	80	Attorney Docket Number	15270J-004765US

NON PATENT LITERATURE DOCUMENTS ¹				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
KAB	640	JUNG et al., "Alzheimer's Beta-amyloid Precursor Protein Is Expressed on the Surface of Immediately Ex Vivo Brain Cells: a Flow Cytometric Study," <u>J. Neurosci. Res.</u> , 46:336-348 (1996).		
	729	KASCSAK et al., "Mouse Polyclonal and Monoclonal Antibody to Scrapie-Associated Fibril Proteins," <u>J. Virology</u> , 61(12):3688-3693 (1987).		
	628	KOFER et al., "Mechanism of Allergic Cross-Reactions--III. cDNA Cloning and Variable- Region Sequence Analysis of Two IgE Antibodies Specific for Trinitrophenyl," <u>Mol.</u> <u>Immunology</u> , 29(2):161-166 (1992).		
	627	KRISHNAN et al., "Correlation Between the Amino Acid Position of Arginine in VH-CDR3 and Specificity for Native DNA Among Autoimmune Antibodies ^{1,2} ," <u>J. Immunol.</u> , 157(6):2430-2439 (1996).		
	695	KUO et al., "Water-soluble A β (N-40, N-42) Oligomers in Normal and Alzheimer Disease Brains," <u>J. Biol. Chem.</u> , 271(8):4077-4081 (1996).		
	734	KURASHIMA et al., "Production of Monoclonal Antibody against Amyloid Fibril Protein and Its Immunohistochemical Application," <u>Appl. Pathol.</u> , 3(1-2):39-54 (1985).		
	651	LANDOLFI et al., "The Integrity of the Ball-and Socket Joint Between V and C Domains Is Essential for Complete Activity of a Humanized Antibody," <u>J. Immunology</u> , 166(3):1748- 1754 (2001).		
	727	LINKE, "Monoclonal antibodies against amyloid fibril protein AA. Production, specificity, and use for immunohistochemical localization and classification of AA-type amyloidosis," <u>J.</u> <u>Histochemistry and Cytochemistry</u> , 32(3):322-328 (1982).		
	665	LO et al., "High level expression and secretion of Fc-X fusion proteins in mammalian cells," <u>Protein Engineering</u> , 11(6):495-500 (1998).		
	666	MANDEL et al., "Clinical trials in neurological disorders using AAV vectors: promises and challenges," <u>Curr. Opin. Mol. Ther.</u> , 6(5):482-490 (2004).		
	731	MARHAUG et al., "Monoclonal hybridoma antibodies to human amyloid related protein SAA," <u>Clin. Exp. Immunol.</u> , 50(2):390-396 (1982).		
KAB	610	MATTSON et al., "Good and bad amyloid antibodies," <u>Science</u> , 301(5641):1845-1849 (2003).		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.




Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known	
			Application Number	09/724,288
			Filing Date	November 28, 2000
			First Named Inventor	Schenk, Dale B.
			Art Unit	1649
			Examiner Name	Charon L. Turner K. Ballard
			Attorney Docket Number	15270J-004765US
Sheet	8	of	810	

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
KAB	732	MAURY et al., "Immunohistochemical Localization of Amyloid in Finnish Hereditary Amyloidosis with Antibodies to Gelsolin Peptides," <u>Laboratory Investigation</u> , 64(3):400-404 (1991).		
	611	MCLAURIN et al., "Therapeutically effective antibodies against amyloid- β peptide target amyloid- β residues and 4-10 and inhibit cytotoxicity and fibrillogenesis," <u>Nat Med.</u> , 8(11):1263-1269 (2002).		
	612	MONSONEGO et al., "Increased T cell reactivity to amyloid β protein in older humans and patients with Alzheimer's disease," <u>J. Clin. Invest.</u> , 112(3):415-422 (2003).		
	613	MONSONEGO et al., "Immunotherapeutic approaches to Alzheimer's disease," <u>Science</u> , 302(5646):834-838 (2003).		
	652	ORLANDI et al., "Cloning immunoglobulin variable domains for expression by the polymerase chain reaction," <u>PNAS</u> , 86:3833-3837 (1989).		
	614	PAGANETTI et al., "Amyloid precursor protein truncated at any of the γ -secretase sites is not cleaved to β -amyloid," <u>J. Neurosci. Res.</u> , 46(3):283-293 (1996).		
	615	PALLITTO et al., "Recognition sequence design for peptidyl modulators of β -amyloid aggregation and toxicity," <u>Biochemistry</u> , 38(12):3570-3578 (1999).		
	654	PANKA et al., "Variable region framework differences result in decreased or increased affinity of variant anti-digoxin antibodies," <u>PNAS</u> , 85:3080-3084 (1998).		
	682	PARNETTI et al., "Cognitive Enhancement Therapy for Alzheimer's Disease, The Way Forward," <u>Drugs</u> , 53(5):752-768 (1997).		
	653	PAUL, W. E., eds., <i>Fundamental Immunology</i> , Third Edition, pages 292-295, Raven Press, New York (1993).		
	616	PFEIFER et al., "Cerebral hemorrhage after passive anti-A β immunotherapy," <u>Science</u> , 298(5597):1379 (2002).		
KAB	733	PHELPS et al., "Development and Characterization of Monoclonal Antibodies Specific for Amylin," <u>Hybridoma</u> , 15(5):379-386 (1996).		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.




INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	09/724,288	
			Filing Date	November 28, 2000	
			First Named Inventor	Schenk, Dale B.	
			Art Unit	1649	
			Examiner Name	Sharon L. Turner K. Ballard	
Sheet	9	of	810	Attorney Docket Number	15270J-004765US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
KAB	641	RACKE et al., "Exacerbation of Cerebral Amyloid Angiopathy-Associated Microhemorrhage in Amyloid Precursor Protein Transgenic Mice by Immunotherapy Is Dependent on Antibody Recognition of Deposited Forms of amyloid β ," <u>J. Neurosci.</u> , 25(3):629-636 (2005).		
	638	Research Corporation Technology News, "THP and SangStat Partner to Develop Humanized Polyclonal Antibody Drugs," 11/11/02.		
	626	"Researchers Develop Blood Test to Diagnose Alzheimer's- Type Changes in Mice," downloaded from www.businesswire.com on 12/15/04.		
	655	RUDIHOFF et al., "Single amino acid substitution altering antigen-binding specificity," <u>PNAS</u> , 79:1979-1983 (1982).		
	617	SCHMID, R. E., "Study suggest Alzheimer vaccine fix," from www.msnbc.com/news, pages 1-5 (2002).		
	629	SEIDL et al., "Predominant V _H genes expressed in innate antibodies are associated with distinctive antigen-binding sites," <u>PNAS</u> , 96:2262-2267 (1999).		
	618	SELKOE, D. J., "Alzheimer's disease is a synaptic failure," <u>Science</u> , 298(5594):789-791 (2002).		
	622	SERGEANT et al., "Truncated beta-amyloid peptide species in pre-clinical Alzheimer's disease as new targets for the vaccination approach," <u>J. Neurochem.</u> , 85(6):1581-1591 (2003).		
	697	SMALL et al., "Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease," <u>PNAS</u> , 97(11):6037-6042 (2000).		
	620	SOLOMON, B., "Generation and brain delivery of anti-aggregating antibodies against β -amyloid plaques using phage display technology," <u>J. Neural Transm. Suppl.</u> , 62:321-325 (2002).		
	621	SOLOMON, B., "Immunotherapeutic strategies for prevention and treatment of Alzheimer's disease," <u>DNA and Cell Biology</u> , 20(11):697-703 (2001).		
KAB	678	SOUDER et al., "Overview of Alzheimer's disease," <u>Nurs. Clin. N. Am.</u> , 39:545-559 (2004).		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/724,288
				Filing Date	November 28, 2000
				First Named Inventor	Schenk, Dale B.
				Art Unit	1649
				Examiner Name	Charon L. Turner K. Ballard
Sheet	10	of	810	Attorney Docket Number	15270J-004765US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
KAB	700	VALLEIX et al., "Hereditary renal amyloidosis caused by a new variant lysozyme W64R in a French family," <i>Kidney International</i> , 61:907-912 (2002).		
	690	VICKERS, J. C., "A Vaccine Against Alzheimer's Disease," <i>Drugs Aging</i> , 19(7):487-494 (2002).		
	623	WALSH et al., "Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo," <i>Nature</i> , 416(6880):535-539 (2002).		
	624	WASHINGTON UNIVERSITY IN ST. LOUIS SCHOOL OF MEDICINE, "Study gives Clues to Working of Anti-Alzheimer Antibody," downloaded from www.medicine.wustl.edu/~wumpa/news on 12/15/04.		
	676	<i>Webster's New World Dictionary</i> , page 1387, therapeutic (1988).		
	688	<i>Webster's New World Dictionary of American English</i> , Third College Edition, page 1078 (1988).		
	625	WHITE et al., "Immunotherapy as a therapeutic treatment for neurodegenerative disorders," <i>J. Neurochem.</i> , 87(4):801-808 (2003).		
KAB	728	YAMADA et al., "Generation and Characterization of Rat Monoclonal Antibodies Against Human Serum Amyloid A," <i>Scand. J. Immunol.</i> , 46(2):175-179 (1997).		

Examiner Signature	/Kimberly Ballard/	Date Considered	06/16/2006
-----------------------	--------------------	--------------------	------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.